No I haven't Hc, I figure the information must be sensitive. I am a glass half full, and if management aren't saying anything, then no news is probably good news. They are highly experienced in this area, and would be aware of shareholder frustration. No doubt the top 20 shareholders are also venting their frustration with Invion 103 delays and the fallen share price. The most recent forcast for Invion 103 data was June, so we can't be too far away from an announcement. The clinical trial website was last updated by Invion April 15, and it says they are still recruiting and predict completion October 2015. Logic would say that the 100mg cohorts are finally done, and the final recruiting is for the 300mg dosage with patients with more severe lupus and nephritis. While frustrating, I believe this is good. If it wasn't safe, the recruitment and trial would have been halted, and if the 100mg dosages didn't move IL6 ,would they waste any more time and money ?
Add to My Watchlist
What is My Watchlist?
